BiopharmaTrend.com

Mesoblast

Mesoblast

Public company
MESOBLAST
Melbourne

Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC)
technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes and kidney
disease, orthopedic spine conditions, and cardiovascular disorders.


Founded
2004
Status
Public company
Geography
Australia based
Funding
$56.200 M
Patents
67
Research papers
26
Clinical Trials
35

Products

No products posted yet

Services

No services posted yet


This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page